Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

Nepexto will be promoted by Generic Health, BBL's local partner and a leading provider of high-quality generic prescription, ...

Biocon Biologics launches Nepexto, a biosimilar for autoimmune diseases like rheumatoid arthritis, in Australia. The drug ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto(R), a biosimilar to the reference ...

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...

When Indian biotechnology firm Biocon and the world's biggest pharma company Pfizer announced their $350-million alliance in late October, the industry took it as another biotech pharma deal--by ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results and engaging in active corporate actions.

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it ...